Arcus Biosciences, Inc. Incremental Common Shares Attributable to Dilutive Effect of Contingently Issuable Shares
Arcus Biosciences, Inc. (RCUS) reported Incremental Common Shares Attributable to Dilutive Effect of Contingently Issuable Shares of 7.59 thousand shares for the 3-month period ending 2020-09-30, per its 10-Q filed 2021-11-08.
Discontinued › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToContingentlyIssuableShares · last filed 2021-11-08
- Arcus Biosciences, Inc. incremental common shares attributable to dilutive effect of contingently issuable shares for the quarter ending 2020-09-30 was 7.59K shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Contingently Issuable Shares 3 month |
|---|---|
| 2020-09-30 | 7.59K shares 10-Q · filed 2021-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |